Onchilles Pharma, a San Diego-based biotech company, presented promising preclinical data at the AACR annual meeting, showing a new molecule to be effective in treating all cancer types. Unlike other cancer treatments that target specific mutations, this molecule has variability and a nonspecific mechanism of action, making it unique. They plan to begin Phase 1 clinical trials later this year, after successfully testing the molecule on 60 different cancer types spanning 13 different anatomical locations. The first study is expected to show reductions in tumor size. For more on Onchilles' ground-breaking research, subscribe to SDBJ.com. https://lnkd.in/gR-rCQzE
San Diego Business Journal’s Post
More Relevant Posts
-
📰 #NSCLC | ASCO24: J&J's subQ Rybrevant matches efficacy, shrinks infusion time in Phase III trial "The PALOMA-3 trial, presented Friday at the American Society of Clinical Oncology (ASCO) annual meeting, is testing the SC formulation of J&J's EGFR/MET-targeting bispecific antibody in 418 patients with EGFR-mutated, advanced or metastatic non-small-cell lung cancer (NSCLC) and exon 19 deletion or L858R mutations [...]" https://hubs.ly/Q02zY4Bq0 FirstWord Pharma
To view or add a comment, sign in
-
[ 🔔 📢 NEW PUBLICATION-WHITE PAPER: Histology Independent Drug Development – Is This the Future for Cancer Drugs?] The Cancer Drug Development Forum (CDDF) is delighted to announce that the White Paper has been developed following its ‘Histology Independent Drug Development – Is This the Future for Cancer Drugs?’ workshop, which took place on 14-15th November 2022, in Amsterdam. The hybrid meeting was set up to explore the current landscape of histology independent drug development, review the current regulatory landscape and propose recommendations for improving the conduct of future trials. 🔔📑 Read the full article published in Cancer Treatment Reviews here: https://lnkd.in/ebgtynQA #Cancer #oncologytrials #HistologyIndependent #Tumour #Biomarkers #DataSharing
To view or add a comment, sign in
-
During my college and med school years, the #HumanGenomeProject was in full swing. As a self-proclaimed nerd, I was thrilled by the potential of sequencing the human genome. Last week, I felt that same excitement at an internal meeting discussing the Cell Surfaceome. This initiative holds immense promise for oncology drug development, particularly in the use of radioligands, antibody-drug conjugates (ADCs), and other innovative therapies. For those interested in learning more, this article is a great place to start: Elucidating the Cell Surfaceome to Accelerate Oncology Drug Development. #RLT #AACR #DrugDevelopmemt #Oncology #Cancer #Surfaceome Novartis https://lnkd.in/gvaUeDst
To view or add a comment, sign in
-
In this study, our collaborators at Grey Wolf Therapeutics have shown that inhibition of ERAP2 modulates the presented HLA class I #immunopeptidome. 🎉 Grey Wolf leveraged our #TrueDiscovery® Immunopeptidome Profiling services to identify an increase in 9-mers and a reduction in 8-mers HLA I peptides upon inhibition of ERAP2. 🚀 Download the poster. https://lnkd.in/dZuaifND #Oncology #Proteomics #MassSpectrometry✨
Now available for download! | Grey Wolf SITC2023 poster on ERAP2 inhibition for cancer immunopeptidome modulation
biognosys.com
To view or add a comment, sign in
-
I am excited to see, what MS-based proteomics can deliver for immunopeptidomics drug development: Measurement of global immunopeptide length shift. Since often, immunopeptides are the ultimate readout and effectors, their direct and comprehensive measurement is key. I am looking forward to more impact! #immunooncology #immunology #massspectrometry #proteomics #immunopeptidomics
In this study, our collaborators at Grey Wolf Therapeutics have shown that inhibition of ERAP2 modulates the presented HLA class I #immunopeptidome. 🎉 Grey Wolf leveraged our #TrueDiscovery® Immunopeptidome Profiling services to identify an increase in 9-mers and a reduction in 8-mers HLA I peptides upon inhibition of ERAP2. 🚀 Download the poster. https://lnkd.in/dZuaifND #Oncology #Proteomics #MassSpectrometry✨
Now available for download! | Grey Wolf SITC2023 poster on ERAP2 inhibition for cancer immunopeptidome modulation
biognosys.com
To view or add a comment, sign in
-
Want to count cells like Iovance Biotherapeutics, Inc.? Use a NucleoCounter® An exciting cancer immunotherapy study by Iovance Biotherapeutics, Inc. https://okt.to/eaxfqX showed that their Gen 2 tumor-infiltrating lymphocyte (TIL) manufacturing process produces effective drug products for adoptive cell transfer (ACT) across five different solid tumor types 💉 The process currently used to produce Lifileucel for melanoma proved highly reproducible, as shown by the NucleoCounter® NC-200™. Key findings included: - Comparable manufacturing success rates across drug products - High purity TILs yielded by the Gen 2 processes for all indications - Robust IFN-γ response upon reactivation Want to elevate your processes? Book a NucleoCounter® NC-202™ demo: https://okt.to/7Y36P0 🤝 #ChemoMetec #NucleoCounter #IovanceBiotherapeutics #Cellcounting
To view or add a comment, sign in
-
Visit our AACR 2024 poster with Sanofi to learn about our recent study investigating spatiotemporal tumor immune modulation with different mono- or combined cancer therapeutics. Our research included the use of antibody I/O agents at different time points and drug concentrations that were introduced simultaneously into a tumor with the Kibur NanoNail. Check out the details of this exciting study at the link provided! #AACR2024 #Sanofi #cancerresearch #KiburMedical #NanoNail
Kibur Medical and Sanofi are presenting the results of a recent study with the Kibur Medical NanoNail™ entitled: “Spatiotemporal tumor immune modulation by localized delivery of cancer therapeutics using an implantable microdevice”. Please join us on April 8, 9AM-12:30PM at Poster Section 28/Number 10. The abstract can be viewed here: https://lnkd.in/d8dzyxCm
To view or add a comment, sign in
-
Want to count cells like Iovance Biotherapeutics, Inc.? Use a NucleoCounter® An exciting cancer immunotherapy study by Iovance Biotherapeutics, Inc. https://okt.to/p9lL05 showed that their Gen 2 tumor-infiltrating lymphocyte (TIL) manufacturing process produces effective drug products for adoptive cell transfer (ACT) across five different solid tumor types 💉 The process currently used to produce Lifileucel for melanoma proved highly reproducible, as shown by the NucleoCounter® NC-200™. Key findings included: - Comparable manufacturing success rates across drug products - High purity TILs yielded by the Gen 2 processes for all indications - Robust IFN-γ response upon reactivation Want to elevate your processes? Book a NucleoCounter® NC-202™ demo: https://okt.to/zxroU6 🤝
To view or add a comment, sign in
-
Want to count cells like Iovance Biotherapeutics, Inc.? Use a NucleoCounter® An exciting cancer immunotherapy study by Iovance Biotherapeutics, Inc. https://okt.to/RmqB6y showed that their Gen 2 tumor-infiltrating lymphocyte (TIL) manufacturing process produces effective drug products for adoptive cell transfer (ACT) across five different solid tumor types 💉 The process currently used to produce Lifileucel for melanoma proved highly reproducible, as shown by the NucleoCounter® NC-200™. Key findings included: - Comparable manufacturing success rates across drug products - High purity TILs yielded by the Gen 2 processes for all indications - Robust IFN-γ response upon reactivation Want to elevate your processes? Book a NucleoCounter® NC-202™ demo: https://okt.to/1sZz4E 🤝
To view or add a comment, sign in
-
Want to count cells like Iovance Biotherapeutics, Inc.? Use a NucleoCounter® An exciting cancer immunotherapy study by Iovance Biotherapeutics, Inc. https://okt.to/3V8kHA showed that their Gen 2 tumor-infiltrating lymphocyte (TIL) manufacturing process produces effective drug products for adoptive cell transfer (ACT) across five different solid tumor types 💉 The process currently used to produce Lifileucel for melanoma proved highly reproducible, as shown by the NucleoCounter® NC-200™. Key findings included: - Comparable manufacturing success rates across drug products - High purity TILs yielded by the Gen 2 processes for all indications - Robust IFN-γ response upon reactivation Want to elevate your processes? Book a NucleoCounter® NC-202™ demo: https://okt.to/6vpxSK 🤝
To view or add a comment, sign in
19,571 followers